We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Catabasis Pharmaceuticals to Present at Upcoming Investor and Industry Conferences

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

-- Needham & Company’s 11th Annual Healthcare Conference, being held April 3-4 at the New York Palace Hotel in New York City. Dr. Jirousek will give a company presentation at 3:40 p.m. on Tuesday, April 3. This conference is a high-impact forum for institutional investors and venture capital firms to hear the latest updates from senior management teams of both public and private companies in sectors such as biotechnology, specialty pharmaceuticals, diagnostics and medical technology.

-- 2nd Diabetes Summit, being held April 19-20 at the Hyatt Harborside in Boston. Dr. Jirousek will present an overview of CAT-1004 as a novel new chemical entity for treating type 2 diabetes in the session “Clinical Drug Development in Diabetes” at 4:05 p.m. on Thursday, April 19. This conference will bring together the leading experts on diabetes from both industry and academia to discuss novel targets for diabetes, lessons to learn from current clinical drug development, and business strategies and opportunities under the current regulatory landscape.

-- Future Leaders in the Biotech Industry, being held April 20 at the Millennium Broadway Hotel & Conference Center in New York City. Dr. Jirousek will give a presentation on Catabasis’ novel approach to drug development at 3 p.m. The presentation will feature an overview of the company, proprietary chemistry platform and promising pipeline, including CAT-1004. This conference will showcase companies best positioned to provide market leadership and will continue to emphasize fresh investment opportunities.